HR and breast cancer: This trial evaluated the efficacy of 125 mg QD palbociclib (3 weeks on/1 week off) with 500 mg fulvestrant (q4w) versus 500 mg fulvestrant q4w in 521 metastatic HR+/HER2− BC patients.